---
title: Publications
description: Publications by AHRM Inc. a global CRO with a focus in Health Economics and Outcomes Research
---

[![](https://www.ahrminc.com/hs-fs/hubfs/Ahrminc/AHRM.Logo.jpg?width=600&height=300&name=AHRM.Logo.jpg)](https://www.ahrminc.com/)

*                  [Global CRO with a Focus in Health Economics and Outcomes Research (HEOR)](https://www.ahrminc.com/services)*

- [Home Page](https://www.ahrminc.com/old-home)
- [About Us](https://www.ahrminc.com/about-old)
- [Services](https://www.ahrminc.com/services) 
    - [Experience](https://www.ahrminc.com/research)
- [Publications](https://www.ahrminc.com/publications-old)
- [Blog](https://ahrminc.hs-sites.com/blog)
- [News/Events](https://ahrminc.hs-sites.com/news-events)
- [Careers](https://www.ahrminc.com/careers)
- [Contact Us](https://www.ahrminc.com/contact) 
    - [Investigator Registration DB](http://www.surveygizmo.com/s3/2194491/PI-Site-Database)
- [Trial Log-in](https://www.ahrminc.com/trials)

![AHRM Buffalo COE](https://www.ahrminc.com/hs-fs/file-28809895-jpg/images/banner-ahrm-office.jpg)

# Publications

1. Tyson C, Pimentel M, Magar R. [Estimating Diagnostic Costs Associated with a Second-Generation Blood Test For Anti-Vinculin and Anti-Cytolethal Distending Toxin B (CdtB) Biomarkers in Comparison to the Standard Exclusionary Approach For Irritable Bowel Syndrome with a Diarrheal Component (IBS-](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/100770)[D/M)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/100770). Presented at ISPOR 2020, Orlando (Virtual), USA. May 2020. 
2. Bernstein JA, **Tyson C,** Relan A, Adams P, **Magar R.** [Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema](https://www.jmcp.org/doi/10.18553/jmcp.2019.19217). J Manag Care Spec Pharm, 2020 Feb;26(2):203-210*.*
3. Kee-Ming Shu M, Fan K, Karikari K, **Tyson C**, Eddib A. [Post-Operative](http://www.remedypublications.com/open-access/post-operative-short-term-outcomes-of-robotic-assisted-sacrocolpoperineopexy-versus-sacrocolpopexy-5473.pdf)[Short-Term Outcomes of Robotic-Assisted Sacrocolpoperineopexy](http://www.remedypublications.com/open-access/post-operative-short-term-outcomes-of-robotic-assisted-sacrocolpoperineopexy-versus-sacrocolpopexy-5473.pdf)[versus Sacrocolpopexy.](http://www.remedypublications.com/open-access/post-operative-short-term-outcomes-of-robotic-assisted-sacrocolpoperineopexy-versus-sacrocolpopexy-5473.pdf) Clinics in Surgery. 2019; 4: 2661.
4. **Tyson C**, Relan A, Adams P, **Magar R. **[Cost-Effectiveness Model for On-Demand Treatment of HAE Attacks](https://www.ahrminc.com/hubfs/AMCP%20Annual%20Meeting%20March%202019/AMCP2019Poster_FINAL_OnDemandHECON_ul26MAR2019.pdf). Presented at AMCP Annual Meeting 2019, San Diego, CA, USA. 2019; 25(3a): S37-S38
5. Shu M, Fan K, Karikari K, **Tyson C**, Eddib A. Post-Operative Short-Term Outcomes of Robotic Sacrocolpoperineopexy versus Robotic Sacrocolpopexy. Podium Presentation at the 48th AAGL Global Congress of Minimally-Invasive Surgery 2019, Vancouve, BC, CA.
6. Fabian R, **Tyson C,** Tuma PL, Pegg IL, and Sarkar A. [A Horizontal Magnetic Tweezers and Its Use for Studying Single DNA Molecules. Micromachines.](https://doi.org/10.3390/mi9040188) 2018; 9(4): 188.
7. **Tyson C**, Shafran I, Hilal R, Chalasani R, Good L, Taxman T, Maheshwari S, Silver HS, Glamour TS, Wallis BJ, Bradshaw T, Shaw A, **Dalfonso LL, Magar R**. [Economic and Clinical Impact of Serum-Derived Bovine Immunoglobulin / Protein Isolate (SBI) in the Management of Chronic Diarrhea in Inflammatory Bowel Disease (IBD)](https://www.valueinhealthjournal.com/article/S1098-3015(17)31766-7/fulltext). Presented at ISPOR 20th Annual European Congress, Glasgow, Scotland. November, 2017.
8. Pimentel M, **Purdy C**, **Magar R**, Rezaie A. [A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome.](http://www.clinicaltherapeutics.com/article/S0149-2918(16)30309-5/fulltext) Clinical Therapeutics. 2016; 38(7):1638-1652
9. McAndrew CP, **Tyson C**, Zischkau J, Mehl P, Tuma PL, Pegg IL, Sarkar A. [Simple horizontal magnetic tweezers for micromanipulation of single DNA molecules and DNA–protein complexes](https://www.ahrminc.com/hubfs/BTN_A_000114369_O_251785a.pdf). BioTechniques. 2016; 60(1):21–27
10. **Tyson C**, McAndrew CP, Tuma PL, Pegg IL, Sarkar A. [Automated Nonparametric Method for Detection of Step-Like Features in Biological Data Sets](https://www.ahrminc.com/hubfs/cytoa22631.pdf). Cytometry Part A. 2015; 87A:393-404.
11. **Purdy C**, Bytzer PM, Pimentel M, **Magar R**. [A novel IBS diagnostic blood panel can enhance a positive diagnostic strategy versus a strategy of exclusion for patients with diarrhea predominant irritable bowel syndrome (IBS-D): Cost implications for Denmark.](https://www.valueinhealthjournal.com/article/S1098-3015(15)02711-4/fulltext) Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
12. Pimentel M, **Purdy C**, **Magar R**. [Cost-minimization for a novel diagnostic blood panel versus standard exclusionary diagnostic testing for diarrhea predominant irritable bowel syndrome: A United States perspective.](https://www.valueinhealthjournal.com/article/S1098-3015(15)02712-6/fulltext) Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
13. Schmulson MJ, Castillo Barradas M, Pimentel M, **Magar R**, **Purdy C**. [Impact of a novel IBS diagnostic blood panel for Mexico: Cost implications to the Mexican private practice for diarrhea predominant irritable bowel syndrome (IBS-D).](https://www.valueinhealthjournal.com/article/S1098-3015(15)02713-8/fulltext) Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
14. Soubieres A, Pimentel M, **Purdy C**, **Magar R**. [Inclusion of a novel IBS blood panel for diagnosing diarrhea predominant irritable bowel syndrome (IBS-D): A UK perspective.](https://www.valueinhealthjournal.com/article/S1098-3015(15)02710-2/fulltext) Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
15. Gabbani T, Violanti C, Deiana S, Pimentel M, **Purdy C**, **Magar R**. [Potential for cost savings associated with a novel IBS blood panel for diagnosing diarrhea predominant irritable bowel syndrome (IBS-D): Italian perspective.](https://www.valueinhealthjournal.com/article/S1098-3015(15)02709-6/fulltext) Presented at ISPOR 18th Annual European Congress, Milan, IT. 2015.
16. Reddy A, Policastro A, Reppine A, Sekab J, **Purdy C**, **Dalfonso L**, **Magar R**. [Assessing Migraine: An Enquiry into Prophylactic Treatment Patterns by Diagnosis: The AMEND Study.](http://www.neurology.org/content/84/14_Supplement/P3.042) Presented at American Academy of Neurology Annual Meeting, Washington, DC. 2015.
17. Bernstein MA, **Purdy CH**, Becker A, **Magar R**. [Three-Year Cost-effectiveness Model for Non-Animal Stabilized Hyaluronic Acid and Dextranomer Copolymer Compared With Sacral Nerve Stimulation After Conservative Therapy for the Management of Fecal Incontinence.](https://www.sciencedirect.com/science/article/pii/S0149291814002082) Clinical Therapeutics. 2014; 36-6:890-905.
18. Gupta A, Lehman H, **Dalfonso L**, Gressani C, **Purdy C**, Wetzel L, **Magar R**. [A Prospective Pilot Study Evaluating the HRQOL Impact of a Novel Air Purification Technology for Pediatric Asthma Patients.](http://www.valueinhealthjournal.com/article/S1098-3015(14)01096-1/fulltext) Presented at ISPOR Annual International Meeting, Montreal, QC, CA. 2014.
19. Blumenfeld A, Inocelda A, Cunanan C, **Purdy C**, **Dalfonso L**, **Magar R**. [The Durability of OnabotulinumtoxinA for the Treatment of Chronic Migraine: CLARITY Pilot Study.](http://www.neurology.org/content/82/10_Supplement/P7.186) Presented at American Academy of Neurology Annual Meeting, Philadelphia, PA. 2014.
20. Tzoulis C, Kent R, Robertson A, Maltman J, **Purdy C**, **Magar R**. [The Retrospective Evaluation of the Dose of IncobotulinumtoxinA and OnabotulinumtoxinA for the Clinical Management of Cervical Dystonia and Blepharospasm: TRUDOSE Pilot Study.](http://www.neurology.org/content/82/10_Supplement/P7.065) Presented at American Academy of Neurology Annual Meeting, Philadelphia, PA. 2014.
21. Blumenfeld A, Inocelda A, Cunanan C, **Purdy C**, **Dalfonso L**, **Magar R**. [Long-term treatment of chronic migraine with onabotulinumtoxinA: CLARITY pilot study.](http://www.jpain.org/article/S1526-5900(14)00436-2/abstract) Presented at the 33rd Annual Scientific Meeting of the American Pain Society, Tampa, FL. 2014.
22. Gärtner M, Petzel M, Kublanck A, Eckert R, Schmidtke M, **Purdy C**, **Magar R**, **Dalfonso L**, Walters C. [A Non-interventional Retrospective Evaluation of Resources Consumed During the Provision of Care for Overactive Bladder Syndrome: A Real World Evaluation (The REDUCE Study - Interim Analysis).](https://www.ics.org/2013/slot/12273) Presented at the International Continence Society Annual Meeting, Barcelona, Spain. 2013.
23. Indig M, **Purdy C**, **Magar R**, **Dalfonso L**, Walters C, Nazir J. [A Non-Interventional Retrospective Evaluation of Resources Consumed During the Provision of Care for Overactive Bladder Syndrome: A Real Worl Evaluation: German Perspective (The REDUCE Study).](http://www.valueinhealthjournal.com/article/S1098-3015(13)03785-6/abstract) Presented at ISPOR 16th Annual European Congress, Dublin, Ireland. 2013.
24. Wexner SD, Bernstein M, **Purdy C**, **Magar R**. [A five-year Markov model evaluating the cost-utility of NASHA/DX for the treatment of fecal incontinence: A United States perspective.](https://www.valueinhealthjournal.com/article/S1098-3015(12)02632-0/fulltext) Presented at ISPOR 15th Annual European Congress, Berlin, DE. 2012.
25. Pimentel M, Schoenfeld P, **Purdy CH**, Gilbert C, **Magar R**. [Cost Savings Associated With Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome](https://www.ajmc.com/journals/issue/2012/ajpb_mayjun2012/cost-savings-associated-with-rifaximin-for-diarrhea-predominant-irritable-bowel-syndrome). American Journal of Pharmacy Benefits. 2012;4(3):e65-e72.
26. Yoelin S, Caulkins C, **Magar R, Purdy C, Dalfonso L.** Interim Analysis of A Non-Interventional Observational And Medical Records Review of Patient Outcomes With Bimatoprost Ophthalmic Solution 0.03% for The Treatment of Hypotrichosis of The Eyelashes. Presented at World Congress of Dermatology, Seoul, Korea. 2011.
27. Santos-Oliveira R, **Purdy C**, da Silva MP, Dos Anjos Carneiro-Leão AM, Machado M, Einarson TR. [Haemoglobin A(1c) levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts](https://link.springer.com/content/pdf/10.1007%2Fs00125-011-2078-8.pdf). Diabetologia. 2011; 54(6):1327-34.
28. Henderson D, **Purdy C, Magar RM**, Hayward AH. [The Potential Economic Benefits Provided By Combining Cisplatin with Src Inhibitor Kx1-004 for Cancer Regimens](http://dx.doi.org/10.1016/S1098-3015(10)72148-3). Presented at ISPOR 15th Annual International Meeting, Atlanta, GA. 2010.
29. Czyrny JJ, Kaplan RE, Wilding GE, **Purdy CH**, and Hirsh J. [Electrical Foot Stimulation: A Potential New Method of Deep Venous Thrombosis Prophylaxis](http://journals.sagepub.com/doi/abs/10.2310/6670.2010.00001?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed). Vascular. 2010; 18(1):20-27.
30. Canfield M, Keller C, Frydrych L, Ashrafioun L, **Purdy C**, Blondell R. [Prescription Opioid Use Among Patients Seeking Treatment for Opioid Dependence](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882311/pdf/nihms139295.pdf). J Addict Med. 2010; 4:108-113.
31. **Magar R, Purdy C**, Hayward AH, Einarson TR, Burnett AK. Cost-effectiveness Analysis of Histamine Dihydrochloride + Low Dose Interleukin-2 Vs Standard of Care for Remission Maintenance for Acute Myeloid Leukemia Patients in their First Complete Remission: A UK Perspective. Presented at ISPOR 12th Annual European Meeting, Paris, France. 2009.
32. **Purdy CH, Magar RS**, Hayward A, Einarson TR. Comparison of Two Methods to Determine Costs for AML Patients in Remission Maintenance: Model Validation from a UK Perspective. Presented at ISPOR 12th Annual European Meeting, Paris, France. 2009.
33. Hayward AH, **Purdy CH**, Hargrave B, Voltz C, **Magar R**. AIDS Community Services of Western New York: A Comprehensive Model for HIV Care and Prevention. Presented at ISPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI. 2009.
34. Frydrych LM, Greene BJ, Blondell RD, **Purdy CH**. [Self-Help Components and Linkage to Aftercare Following Inpatient Detoxification](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770002/pdf/nihms97456.pdf). J Addict Dis. 2009. 28(1).
35. Hayward AH, **Purdy CH, Magar R**, Iskedjian MI. [Incremental Cost Savings Associated with Bariatric Surgery in WNY](https://www.ahrminc.com/hubfs/PSY61_INCREMENTAL_SAVINGS_ASSOCIATED_WITH_A_DECREA.pdf). Presented at the 11th Annual ISPOR Meeting, Greece. November (2008).
36. Hayward AH, **Purdy CH, Magar R**, Iskedjian MI. The Impact of Bariatric Surgery on Psychological Parameters . DIA, Boston, June (2008).
37. Hayward AH, **Purdy CH**, et al. The Development of a Standardized Clinical Algorithmic Predictor of Weight Loss After Bariatric Surgery: Database Analysis Enables Empirical and Statistical Prediction of Threshold Weight Loss by End of Third Post-Operative Visit. Presented at the 11th Annual ISPOR Meeting, Toronto, May (2008).
38. Wisniewski A, **Purdy CH**, et al. [The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits](https://www.ahrminc.com/hubfs/J069v27n01_01.pdf). J Addict Dis. 2008. 27(1): 1-11.
39. **Magar RS**, Fine PG, White RE.[Expected Cost and Cost Considerations Associated with Opioid Rotation for Chronic Non-Cancer Pain: A Simulation Model](https://www.ahrminc.com/hubfs/S1098-3015(10)65598-2.pdf). Presented at 10th Annual ISPOR Meeting, Dublin, Ireland (2007).
40. Marchetti A, **Magar R**, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, Jech R, Slawek J, Ahmed F. [Retrospective Evaluation of the Dose of Dysport® and BOTOX® in the Management of Cervical Dystonia and Blepharospasm: The REAL DOSE Study](https://www.ahrminc.com/hubfs/Marchetti_et_al-2005-Movement_Disorders.pdf). Movement Disorders, Apr 2005, 20 (8) p937 – 944
41. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, **Magar R**, Martin J [Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records](https://www.ahrminc.com/hubfs/1-s2.0-S0149291802850408-main.pdf). Clin Ther. 2002:24; 378-396.
42. Marchetti A, **Magar R**, Lau H. [Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis](https://www.ahrminc.com/hubfs/MarchettiA_et_al_ClinicalTherapeutics_23_11_2001.pdf). Clin Ther, Nov 2001, 23(11) p1904-21.
43. Marchetti A, **Magar R**, An P. [Clinical and economic impact of new trends in glaucoma treatment](https://www.ncbi.nlm.nih.gov/pubmed/11549985). MedGenMed, Jul 26 2001, 3(4) p6
44. Brashear A, Watts MW, Marchetti A, **Magar R**. [Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review](https://www.ahrminc.com/hubfs/BrashearA_et_al_ClinicalTherapeutics_22_12_2000.pdf). Clin Ther, Dec 2000, 22(12) p1516-24.
45. Marchetti A, Wang L, **Magar R**. [Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin](https://www.ahrminc.com/hubfs/MarchettiA_et_al_ClinicalTherapeutics_22_4_2000.pdf). Clin Ther, Apr 2000, 22(4) p422-38.
46. Marchetti A, **Magar R**, Lau H. RSV Hospitalization Charges for Infants not Prophylaxed and Prophylaxed with Palivizumab. Presented at AAP Annual Meeting Critical Care, Emergency Medicine & Transport Medicine, Boston, MA (2000).
47. Marchetti A, Lau H, **Magar R**. [Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings](https://www.ahrminc.com/hubfs/MarchettiA_et_al_ClinicalTherapeutics_21_4_1999.pdf). Clin Ther, Apr 1999, 21(4) p752-66.
48. Marchetti A, **Magar R**, Fischer J. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Clin Ther, Sep-Oct 1996, 18(5) p953-66.
49. **Magar RS**, Doucette D, Kassam R, Seto W, Einarson TR. Warfarin in atrial fibrillation: a meta-analysis and Pharmacoeconomic analysis. Canadian Journal of Clinical Pharmacology. 1995; 2:109-17.

### WHAT'S HAPPENING

### AHRM Blog

### Subscribe to Email Updates

© 2022 AHRM Inc. |1-888-704-5242 I Buffalo +1-716-881-7548 I Raleigh +1-919-758-8203